TherapeuticsMD, Inc. — Director's Dealing 2023

Jun 29, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2023-06-28

Reporting Person: Rubric Capital Management LP (Director, 10% Owner, See Remarks)
Reporting Person: Rosen David Efraim (Director, 10% Owner, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-28	Common Stock, par value $0.001 per share ("Common Stock")	A	312525	$3.6797	Acquired	2069716	Indirect

Footnotes

F1: The Common Stock was purchased in connection with a Subscription Agreement entered into as of May 1, 2023 between the Issuer and Rubric Capital, as described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023.

F2: This Form 4 is filed by Rubric Capital Management LP ("Rubric Capital") and Mr. David Rosen, with respect to the securities held by certain funds and/or accounts (collectively, the "Rubric Vehicles"). Rubric Capital serves as the investment adviser to the Rubric Vehicles. Mr. David Rosen serves as the Managing Member of Rubric Capital Management GP, LLC, the general partner of Rubric Capital. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.